Dr. Chloe E. Atreya, MD, PhD

Dr. Atreya practices at UCSF Helen Diller Medical Center at Parnassus Heights in San Francisco, California, part of University of California Health.

Dr. Atreya's NPI, 1326058777, was assigned on August 8, 2006. Dr. Atreya graduated from Yale School of Medicine in 2005. Dr. Atreya's California license number on file is A104445.

Dr. Atreya's primary practice is UCSF Helen Diller Medical Center at Parnassus Heights, at 505 Parnassus Ave, Box 0296, San Francisco, CA 94143 in San Francisco County. The practice phone is (415) 353-2733.

Dr. Atreya's primary practice is UCSF Helen Diller Medical Center at Parnassus Heights in San Francisco, California, part of University of California Health. The medical group on file is UCSF Pediatrics. Dmand AI also links Dr. Atreya to 3 more group practices and clinics and 3 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Atreya practices, 4 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Atreya's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Atreya is board certified in medical oncology by the American Board of Internal Medicine. Dr. Atreya has a license on file in California.

Dmand AI lists colorectal cancer, lung cancer and prostate cancer among the conditions Dr. Atreya treats.

CMS data shows 363 Medicare services from Dr. Atreya across 5 procedure codes in 2024, for 115 Medicare patients. Medicare paid $34,526 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 115 Medicare patients who saw Dr. Atreya in 2024. The largest group is 65 to 74, with 59 patients. 75% of them have cancer, and 64% have high blood pressure. 25% are also on Medicaid. Their average risk score is 2.27, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Atreya's median patient age at 65, with 61% women.

In 2024, Dr. Atreya wrote 190 Medicare Part D claims for 31 patients. 59% of them were for generic drugs. CMS names the drug for 125 of them, across 5 drugs with 11 or more claims each, at $525,563 in total drug cost. In 2023, CMS named 111 claims across 6 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Atreya for performance year 2024, reported as part of a group. Dr. Atreya accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Atreya as offering telehealth.

Dmand AI links 82 papers to Dr. Atreya, published from 2002 to 2025. 2020 was the busiest year, with 11. The most frequent topics are Colorectal Neoplasms, Antineoplastic Combined Chemotherapy Protocols and Proto-Oncogene Proteins B-raf. Dr. Atreya has published most often in J Clin Oncol. Dr. Atreya's most frequent co-authors are Alan P. Venook, MD, Sorbarikor Piawah, MD and Carling Ursem, MD.

Dmand AI links Dr. Atreya to 8 clinical trials, 3 of them phase 2 studies. 1 is still active or recruiting. Conditions studied include Rectal Diseases, Colorectal Neoplasms and Rectal Neoplasms. University of California, San Francisco sponsors the most, 7.

CMS Open Payments shows 11 general payments to Dr. Atreya from 3 drug and device companies from 2016 to 2024. Consulting fees make up the largest share, 68% of the total. Genentech, Inc. paid the most, $9,170.

Dmand AI lists 1 award for Dr. Atreya, most recently CMS Stage 1 EHR in 2013.

Dr. Atreya graduated from Yale School of Medicine in 2005.

Dr. Atreya is in network with 6 carriers, including Aetna, Blue Cross Blue Shield of Michigan and Blue Cross Blue Shield of Massachusetts. Medicare plans come from the most carriers, 6. Check the plan with the practice before a visit.